Oncoethix

Founded in 2009, Oncoethix is a Swiss-based privately held biotechnology Company that is developing a small portfolio of oncology drug candidates. The Company’s lead product, OTX015, is an orally administered synthetic small molecule targeted to BET bromodomain proteins 2/3/4. OTX015 was in-licensed from Mitsubishi Tanabe Pharma Corporation in March 2012 following completion of Phase 1 clinical studies in healthy volunteers.